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Fibroblast growth factor (FGF) 21 belongs to a superfamily of 
FGF peptides predominantly produced by the liver but also by 
other tissues involved in carbohydrate and lipid metabolism. 
FGFs are classically considered to be paracrine factors, but the 
FGF19, FGF21, and FGF23 subfamily has recently become 
known as a group of endocrine factors [1]. 
  FGF21 expression is induced in the murine liver by fasting 
as an adaptive response through a mechanism requiring per-
oxisome proliferator-activated receptor alpha (PPARα) [2]. In 
the liver, FGF21 induces gluconeogenesis, fatty acid oxidation, 
and ketogenesis but does not stimulate glycogenolysis [2,3]. It 
suggests that FGF21 does not play a conspicuous role during 
the early stage of fasting. However, FGF21 stimulates gluconeo-
genesis and ketogenesis in a state of prolonged fasting and star-
vation. In fact, an increase in plasma FGF21 during 72-hours 
fasting was absent, but the effect was present during 7-days of 
starvation in human studies [4,5].
  There is evidence that FGF21 is a promising target for the 
treatment of type 2 diabetes and metabolic syndrome. When 
administrated systemically to rodents and monkeys with obe-
sity and diabetes, recombinant FGF21 causes body weight loss, 
decrease of plasma glucose and triglycerides, and reduction of 
insulin resistance and hepatic steatosis [6-9] although little is 
known about the physiologic roles or regulation of FGF21 in 
humans. FGF21 treatment potently stimulates glucose uptake 
in adipocytes in an insulin-dependent manner [7]. In obese, 
insulin-resistant animals, FGF21 regulates mitochondrial ac-
tivity and enhances oxidative capacity through an AMPK–
SIRT1–PGC1α–dependent mechanism in adipocytes [10] and 
decreases hepatic triglyceride contents associated with a de-
crease in hepatic lipogenic gene expression (e.g., sterol regula-
tory element-binding protein-1 [SREBP-1]) [9]. 
  The 24-hour circadian rhythm of FGF21 is displayed under 
fasting conditions in both humans and mice [4,11]. FGF21 
levels began to rise at midnight, reaching a peak in the early 
morning and then decline to basal concentrations early in the 
afternoon [4,11]. A number of metabolic hormones including 
leptin, growth hormone, melatonin, and cortisol have been 
shown to exhibit a nocturnal increase. In addition, E4-binding 
protein 4 (E4BP4), which is a key circadian output protein 
transcriptional repressor, directly bound to the D-box cis-ele-
ment in the distal promoter region of the FGF21 gene and 
downregulated its transcription and secretion in primary 
mouse hepatocytes [12]. Insulin significantly increases E4BP4 
expression, which can subsequently repress hepatic FGF21 ex-
pression [12]. Other key factors of the circadian clock that 
regulate the hepatic expression of FGF21 in cultured cells are 
retinoic acid receptor-related orphan receptor α (RORα) and 
Rev-Erbα [13,14].
  However, Lee et al. [15] were unable to observe a distinct 
diurnal variation of serum FGF21 concentrations over 24-hours 
in a small group of healthy Korean men (n=10) fed standard-
ized meals. Although the basis for these differences is not clear, 
the methods of the FGF21 assay and the characteristics of 
study subjects could have caused the discrepancy. Because 
most studies on circadian variation of FGF21 were performed 
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using a fasting state, feeding-dependent FGF21 expression may 
be different in liver and adipose tissues [16]. The molecular 
mechanism responsible for feeding-induced regulation of 
FGF21 is less well known than that for fasting-induced stimu-
lation, and further studies in a non-fasting condition should 
be performed because they are more physiologically relevant.
  There are many controversial issues regarding serum FGF21 
levels in human studies. In fact, the effects of ketogenic diet on 
circulating FGF21 concentrations in humans are inconsistent 
[5,17,18] and circulating FGF21 concentrations in humans 
showed a broad 250-fold interindividual variation [5]. Al-
though the magnitude of the peak circadian increase of circu-
lating FGF21 is significantly blunted in obese Chinese [11], in 
a study by Lee et al. [15], the number of large oscillations of 
FGF21 concentrations was significantly greater in obese sub-
jects. Several recent reports showed that circulating FGF21 
concentrations were higher in subjects with obesity, type 2 di-
abetes, impaired glucose tolerance, dyslipidemia or nonalco-
holic fatty liver disease than in controls [18-21]. It is unclear 
whether this reflects FGF21 resistance or a compensatory re-
sponse. Although there are few studies to demonstrate the 
physiologic role of FGF21 in the human body, a recent study 
showing that diet-induced obese mice had increased expres-
sion of FGF21 in liver and white adipose tissue with a signifi-
cantly attenuated signaling response to exogenous FGF21 sug-
gests FGF21 resistance in obesity [22].
  Taken together, FGF21 actions to regulate and coordinate 
metabolism have not yet been clarified, especially in humans. 
It is necessary to consider that the regulation of FGF21 is com-
plex and can differ from tissue to tissue, according to nutrition-
al conditions or circadian rhythm. Future investigations about 
the effects of exogenous FGF21 in humans will elucidate the 
possible usefulness of this protein as a novel treatment tool for 
metabolic diseases.
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